BIPAVE-001 is a Phase 1/2 trial designed to evaluate the safety, pharmacokinetic, and efficacy of AI-081. The Part A portion is a first-in-human dose escalation study that will determine the ...

PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones – “PTC518 is the leading oral disease-modifying therapy in development for Huntington’s disease and the economics ...

Preclinical data for both SPY002 molecules demonstrate picomolar potency and potential for quarterly or twice-yearly dosing, suggesting opportunity for improved efficacy and convenience over ...

BENGALURU, Karnataka, India I 01, 2024 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE ...

Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S.

SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically ...

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight ...

NEW HAVEN, CT, USA I November 25, 2024 I Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.

DOVER, DE, USA I6, 2024 I Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 ...